JP2019534706A5 - - Google Patents

Download PDF

Info

Publication number
JP2019534706A5
JP2019534706A5 JP2019520386A JP2019520386A JP2019534706A5 JP 2019534706 A5 JP2019534706 A5 JP 2019534706A5 JP 2019520386 A JP2019520386 A JP 2019520386A JP 2019520386 A JP2019520386 A JP 2019520386A JP 2019534706 A5 JP2019534706 A5 JP 2019534706A5
Authority
JP
Japan
Prior art keywords
antibody
drug conjugate
seq
heavy chain
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019520386A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534706A (ja
JP7039577B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/056093 external-priority patent/WO2018073680A1/en
Publication of JP2019534706A publication Critical patent/JP2019534706A/ja
Publication of JP2019534706A5 publication Critical patent/JP2019534706A5/ja
Priority to JP2021190070A priority Critical patent/JP7383682B2/ja
Application granted granted Critical
Publication of JP7039577B2 publication Critical patent/JP7039577B2/ja
Priority to JP2023191037A priority patent/JP2023184697A/ja
Priority to JP2025146227A priority patent/JP2025175010A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019520386A 2016-10-17 2017-10-03 抗ｅｄｂ抗体および抗体－薬物コンジュゲート Active JP7039577B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021190070A JP7383682B2 (ja) 2016-10-17 2021-11-24 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
JP2023191037A JP2023184697A (ja) 2016-10-17 2023-11-08 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
JP2025146227A JP2025175010A (ja) 2016-10-17 2025-09-03 抗ｅｄｂ抗体および抗体－薬物コンジュゲート

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662409081P 2016-10-17 2016-10-17
US62/409,081 2016-10-17
PCT/IB2017/056093 WO2018073680A1 (en) 2016-10-17 2017-10-03 Anti-edb antibodies and antibody-drug conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021190070A Division JP7383682B2 (ja) 2016-10-17 2021-11-24 抗ｅｄｂ抗体および抗体－薬物コンジュゲート

Publications (3)

Publication Number Publication Date
JP2019534706A JP2019534706A (ja) 2019-12-05
JP2019534706A5 true JP2019534706A5 (enExample) 2020-11-12
JP7039577B2 JP7039577B2 (ja) 2022-03-22

Family

ID=60117722

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019520386A Active JP7039577B2 (ja) 2016-10-17 2017-10-03 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
JP2021190070A Active JP7383682B2 (ja) 2016-10-17 2021-11-24 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
JP2023191037A Pending JP2023184697A (ja) 2016-10-17 2023-11-08 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
JP2025146227A Pending JP2025175010A (ja) 2016-10-17 2025-09-03 抗ｅｄｂ抗体および抗体－薬物コンジュゲート

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021190070A Active JP7383682B2 (ja) 2016-10-17 2021-11-24 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
JP2023191037A Pending JP2023184697A (ja) 2016-10-17 2023-11-08 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
JP2025146227A Pending JP2025175010A (ja) 2016-10-17 2025-09-03 抗ｅｄｂ抗体および抗体－薬物コンジュゲート

Country Status (22)

Country Link
US (5) US20190269791A1 (enExample)
EP (3) EP3525828B1 (enExample)
JP (4) JP7039577B2 (enExample)
KR (1) KR102338660B1 (enExample)
CN (2) CN116251196A (enExample)
AU (3) AU2017344440B2 (enExample)
CA (1) CA3040423A1 (enExample)
DK (1) DK3525828T3 (enExample)
ES (1) ES3007557T3 (enExample)
FI (1) FI3525828T3 (enExample)
HR (1) HRP20250056T1 (enExample)
HU (1) HUE070615T2 (enExample)
IL (2) IL310865A (enExample)
LT (1) LT3525828T (enExample)
MX (2) MX2019004434A (enExample)
PL (1) PL3525828T3 (enExample)
PT (1) PT3525828T (enExample)
RS (1) RS66524B1 (enExample)
RU (1) RU2758632C2 (enExample)
SG (1) SG11201903400WA (enExample)
SI (1) SI3525828T1 (enExample)
WO (1) WO2018073680A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
WO2020123425A2 (en) * 2018-12-12 2020-06-18 Bristol-Myers Squibb Company Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
KR102614063B1 (ko) 2020-12-24 2023-12-19 대화제약 주식회사 엑스트라도메인 b 피브로넥틴에 특이적으로 결합하는 신규한 항체
CN112816453B (zh) * 2021-02-09 2022-07-08 黑龙江大学 蛋白在预测药物性能上的应用
EP4340944A4 (en) * 2021-05-20 2026-04-01 Univ Case Western Reserve Specific Peptide and Drug Conjugates of Fibronectin Isotypes for Cancer Therapy
EP4370541A1 (en) 2021-07-14 2024-05-22 2seventy bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
AU2023248532A1 (en) 2022-04-08 2024-11-21 Regeneron Pharmaceuticals, Inc. Multipartite receptor and signaling complexes
EP4716555A1 (en) * 2023-07-10 2026-04-01 Wuxi Xdc Singapore Private Limited Antibody-drug conjugates and production thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025208105A1 (en) * 2024-03-29 2025-10-02 Pyxis Oncology, Inc. Constructs, compositions, and methods for treating extra domain b splice variant of fibronectin-expressing diseases and disorders

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
WO1997026885A1 (en) 1996-01-23 1997-07-31 The General Hospital Corporation Doing Business As Massachusetts General Hospital Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
EP1259548A1 (en) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
US8623373B2 (en) * 2000-02-24 2014-01-07 Philogen S.P.A. Compositions and methods for treatment of angiogenesis in pathological lesions
AU2002348477A1 (en) 2001-05-01 2002-12-23 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
PL369371A1 (en) * 2002-01-03 2005-04-18 Schering Aktiengesellschaft New methods for diagnosis and treatment of tumours
ES2337566T3 (es) 2002-03-11 2010-04-27 Philogen S.P.A. Anticuerpos derivados de anti ed-b l19 y vasculatura tumoral objetivo.
KR20050026033A (ko) * 2002-07-31 2005-03-14 쉐링 악티엔게젤샤프트 신규 효과기 접합체, 그의 제조 방법 및 그의 약학적 용도
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
MX2007013875A (es) * 2005-05-11 2008-01-28 Philogen Spa Proteinas de fusion del anticuerpo l19 contra fibronectina ed-b e interlucina 12.
RU2467015C2 (ru) 2005-10-05 2012-11-20 Коммонвелт Сайентифик Энд Индастриал Рисерч Организейшн Белки шелка
EP1842553A1 (en) 2006-04-07 2007-10-10 Bayer Schering Pharma Aktiengesellschaft Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule
JP2009535372A (ja) * 2006-05-03 2009-10-01 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 抗ｅｄｂフィブロネクチンドメイン抗体ｌ１９−ｓｉｐ及び抗−ｅｇｆｒ−抗体の組合せ
TWI412367B (zh) * 2006-12-28 2013-10-21 梅達雷克斯有限責任公司 化學鏈接劑與可裂解基質以及其之綴合物
CA2682851C (en) 2007-04-02 2017-01-17 Philogen S.P.A. A novel antigen associated with the neovasculature of tumour metastases
EA017995B1 (ru) 2007-07-25 2013-04-30 Филоджен С.П.А. Антиген, связанный с вариантами рака легкого и лимфомами
EP2085095B1 (en) 2008-01-17 2012-03-07 Philogen S.p.A. Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
PL3912643T3 (pl) * 2009-02-13 2023-01-23 Immunomedics Inc. Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
US8679488B2 (en) 2009-08-05 2014-03-25 Philogen S.P.A. Targeting of bone marrow neovasculature
RU2583876C2 (ru) 2009-08-17 2016-05-10 Роше Гликарт Аг Иммуноконъюгаты направленного действия
BR112012014417B1 (pt) 2009-12-14 2021-11-09 Scil Proteins Gmbh Proteínas ubiquitinas modificadas tendo uma atividade de ligação específica para o extradomínio b de fibronectina
EP3842074A1 (en) 2010-09-29 2021-06-30 Philogen S.p.A. Protein-drug conjugates
CA2813411C (en) * 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2780039B9 (en) 2011-11-17 2018-04-18 Pfizer Inc Cytotoxic peptides and antibody drug conjugates thereof
EP3539982B1 (en) 2011-12-23 2025-02-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EA201591465A1 (ru) * 2013-02-08 2015-12-30 АйАрЭм ЭлЭлСи Специфичные участки для модификации антител для получения иммуноконъюгатов
EP2988784A1 (en) * 2013-04-25 2016-03-02 Philogen S.p.A. Antibody-drug conjugates
SG11201605437YA (en) * 2014-01-27 2016-08-30 Pfizer Bifunctional cytotoxic agents
WO2015114166A2 (en) * 2014-02-03 2015-08-06 Philochem Ag Targeted drug conjugates
KR20190072663A (ko) * 2014-04-25 2019-06-25 리나트 뉴로사이언스 코프. 약물이 고도로 로딩된 항체-약물 접합체
TW201625689A (zh) 2014-09-12 2016-07-16 建南德克公司 抗－ｂ７－ｈ４抗體及免疫結合物
TWI812873B (zh) * 2015-11-30 2023-08-21 美商輝瑞股份有限公司 用於部位專一性接合之抗體和抗體片段
US10689458B2 (en) 2015-11-30 2020-06-23 Pfizer Inc. Site specific HER2 antibody drug conjugates

Similar Documents

Publication Publication Date Title
US11833120B2 (en) Binding protein drug conjugates comprising anthracycline derivatives
Richards Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug delivery
ES2595091T3 (es) Composiciones farmacéuticas con resistencia a CEA soluble
JP2021532831A5 (enExample)
WO2019170131A1 (zh) 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
BR112021011014A2 (pt) Anticorpos anti-claudina e usos destes
JP2018509908A5 (enExample)
CN110869393A (zh) 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
JP2019531084A5 (enExample)
JP2016503295A5 (enExample)
RU2016129894A (ru) Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
JP2017535246A5 (enExample)
WO2012047724A4 (en) Antibody drug conjugates (adc) that bind to 191p4d12 proteins
JP7553633B2 (ja) Ｔｈｏｍｓｅｎ－ｎｏｕｖｅｌｌｅ（ｔｎ）抗原に対するヒト抗体
RU2016150377A (ru) Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc
JP2016531915A5 (enExample)
HRP20231609T1 (hr) Konjugati lijeka koji sadrže antitijela protiv klaudina 18.2
JP2016512832A5 (enExample)
JP2016518332A5 (enExample)
RU2016139340A (ru) Коньюгаты "антитело - лекарственное средство" с высокой лекарственной нагрузкой
JP2010535713A5 (enExample)
FI3525828T3 (fi) Anti-edb-vasta-aineita ja vasta-aine-lääke-konjugaatteja
JP2013519364A5 (enExample)
JP2020504607A5 (enExample)
JP2008515889A5 (enExample)